Show Notes
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jens Juul Holst, Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. We explore the discovery of GLP-1, its evolution into today’s leading therapies for diabetes and obesity, and the molecular and clinical mechanisms that drive their success. Listen now on all major platforms.
“The incretin hormones GLP-1 and GIP amplify insulin secretion after meals, ensuring glucose tolerance and maintaining energy balance across multiple tissues.”
Meet the guest: Dr. Jens Juul Holst is Professor of Medical Physiology at the University of Copenhagen and Senior Group Leader at the Novo Nordisk Foundation Center for Basic Metabolic Research. His research focuses on metabolic hormones, appetite regulation, and the pathophysiology of obesity and type 2 diabetes. Known for co-discovering GLP-1, his work has shaped modern metabolic therapy.
What you will learn: (00:00) Highlight (00:35) Introduction (01:44) GLP-1 mechanism (04:37) Discovery process (07:12) Therapeutic development (10:56) Cardiovascular effects (14:45) Broader metabolic impact (20:04) Final Questions
𝗟𝗶𝘀𝘁𝗲𝗻 𝗼𝗻 𝗔𝗽𝗽𝗹𝗲 𝗣𝗼𝗱𝗰𝗮𝘀𝘁𝘀, 𝗦𝗽𝗼𝘁𝗶𝗳𝘆 𝗼𝗿 𝗮𝗻𝘆 𝗺𝗮𝗷𝗼𝗿 𝗽𝗹𝗮𝘁𝗳𝗼𝗿𝗺. Website: https://www.wisenetix.com/glp1 Instagram: https://www.instagram.com/theglp1podcast/ LinkedIn: https://www.linkedin.com/showcase/the-glp-1-podcast-show/
More from The GLP-1 Podcast Show
In this episode of The GLP-1 Podcast Show, I speak with Dr. Anders Fink-Jensen, Professor of Psychiatry at the University of Copenhagen and a consultant psychiatrist, about the emerging role of GLP-1 receptor agonists in addiction treatment. We examine the clinical observations that initiated this research, findings from a randomized trial of semaglutide for alcohol use disorder, possible effects on craving, dosing considerations, and the evidence still needed before broader clinical use. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Michelle Gordon, a physician board-certified in obesity medicine and CEO of Thrive Span Medical, about obesity care for women in midlife. We discuss how GLP-1 therapy fits into long-term disease management, why slower weight reduction, adequate protein, resistance training, hydration, and fiber matter, and how hormonal changes may affect weight, cognition, and metabolic health. Dr. Gordon also explains when bariatric surgery remains appropriate and why obesity should be treated as a complex chronic disease. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Jon Campbell, Associate Professor of Medicine at Duke University, about the changing science of GIP and glucagon. We examine GIP physiology, glucagon signaling, weight-independent metabolic effects, multi-receptor agonism, and variability in treatment response. Discover how emerging pharmacology could shape more precise obesity treatment. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Ashley Koff, registered dietitian, founder of The Better Nutrition Program, and bestselling author of Your Best Shot, about weight health in the GLP-1 era. She explains why body composition matters more than total weight, how digestion and hydration shape nutrition outcomes, why protein advice must be personalized, and how clinicians can support more sustainable metabolic health. Listen now on all major platforms.
In this episode of The GLP-1 Podcast Show, I speak with Dr. Timothy Garvey, Endowed Professor of Medicine at the University of Alabama at Birmingham, about complication-centric care for Adiposity-Based Chronic Disease. We examine current obesity guidelines, medication selection according to complications, what the key unmet clinical need is in obesity care, and the role of second-generation GLP-1 medications in type 2 diabetes. Listen now on all major platforms.